AsymBio, a leading China-based biologics Contract Development and Manufacturing Organization (CDMO), is excited to announce that it has successfully passed the European Union Qualified Person (QP) Audit. This achievement underscores AsymBio's unwavering commitment to upholding the highest standards of quality and compliance in the biologics industry.

The rigorous audit process, conducted by EU regulatory authorities, validates AsymBio's adherence to stringent guidelines and regulations by the European Union. By passing this audit, AsymBio further solidifies its position as a trusted partner for biopharmaceutical companies seeking cutting-edge solutions backed by exceptional quality assurance.

AsymBio remains committed to driving innovation, fostering collaboration, and ensuring that clients receive the highest level of service and quality throughout their drug development journey.

For more information about AsymBio and its comprehensive biologics CDMO services, visit www.asymbio.com